F-573

N/A

Report date: 2023/11/20 11:18:30
NME

Base Information

Drug NameF-573
Drug Alias NameF-573CV-1013EP-1013MX-1013
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionCaspase inhibitors
TargetsCaspase
Therapy Area/IndicationsHepatitisAcute-On-Chronic Liver FailureLiver Failure, Acute +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesEpicept Corp
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesGni GroupImmune Pharmaceuticals IncBeijing Continent Pharmaceutical Co Ltd +[4] 
Inactive CompaniesContinent Pharmaceuticals Inc
Active IndicationsHepatitisAcute-On-Chronic Liver FailureLiver Failure, Acute +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A